Custom service
Custom HLA/Peptide Tetramer Development
Develop tetramers for new hla alleles or unusual peptide cargo
Custom HLA/Peptide Tetramer Development supports programmes that develop tetramers for new HLA alleles or unusual peptide cargo. In a typical engagement we plan the rare-allele construct design route first, confirm compatibility with refolding condition screening, and release validated tetramer with development report on a 6–9 weeks schedule.
Chemistry is chosen for the molecule, not from a menu. Where the payload tolerates it we keep rare-allele construct design as the primary option and hold refolding condition screening in reserve, so that scale-up never depends on an unproven step.
Rare HLA alleles with no commercial tetramer
Non-canonical peptide cargo such as phospho-epitopes
Alleles with no expression construct available
Alleles or peptides with no published refolding precedent and no feasibility budget
Each tetramer lot is tested functionally, not just biochemically: a known antigen-specific T cell line or clone is stained, and the lot is released only if the staining profile meets the agreed specification. Allele and peptide identity are confirmed by MS.
Service Highlights
- Rare-allele construct design as the default route, with refolding condition screening held as a proven fallback
- Stability (decay) assay QC worked into the design where the application requires it
- Refolding yield and monomer integrity confirmed by SEC before tetramerization
- Analytical confirmation of every intermediate before the final release
- Fluorescent labels chosen and titrated so staining signal stays in the linear range
- Validated tetramer with development report delivered with a complete conjugation or synthesis certificate
How the work runs
Construct design
Allele, peptide and biotinylation acceptor peptide are confirmed, and the expression construct strategy is agreed.
Inclusion body preparation
Heavy chain and β2-microglobulin are expressed and purified as inclusion bodies.
Refolding
Chain, β2M and peptide are folded together under redox-buffered conditions optimized for the allele.
Biotinylation & purification
Monomer is BirA-biotinylated and polished by SEC-HPLC to remove aggregates.
Tetramerization
Fluorescent streptavidin is titrated in to form stable tetramers with controlled label ratio.
Functional release
Validated tetramer with development report is released after flow-cytometry binding confirmation against the specification.
Specifications & timeline
- Turnaround
- 6–9 weeks
- Typical scale
- 50 µg – 1 mg tetramer per construct
- Chemistry options
- rare-allele construct design; refolding condition screening; stability (decay) assay QC
- Deliverable
- Validated tetramer with development report
- QC package
- SEC-HPLC monomer integrity, biotinylation ratio, flow-cytometry binding test
- Shipping
- Dry ice, aliquoted to avoid freeze-thaw
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.